GlassScriptPhysician profile
Brian C Barton
NPI 1548693989
$1,858.87
in general payments reported to CMS, 2019-2025
23 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $295 · 2023: $356 · 2024: $407 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $242.51 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $191.87 | 2021-2025 | Verquvo, Capvaxive, Steglatro |
| Corium, LLC | $165.13 | 2022-2024 | Azstarys, Azstarys |
| Lundbeck LLC | $140.73 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $132.56 | 2021-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $118.30 | 2021-2024 | Breztri, Airsupra |
| Lilly USA, LLC | $112.45 | 2021-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $99.93 | 2021-2025 | |
| Pfizer INC. | $96.52 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $94.87 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $93.98 | 2022-2025 | Rexulti |
| Amgen INC. | $74.06 | 2023-2025 | Repatha, Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $64.34 | 2022 | |
| Collegium Pharmaceutical, INC. | $35.53 | 2025 | Jornay Pm |
| Mylan Specialty L.P. | $28.48 | 2024 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $27.27 | 2021-2022 | |
| Novo Nordisk INC | $27.21 | 2022-2025 | |
| Viatris Specialty LLC | $25.66 | 2025 | Yupelri |
| Dexcom, INC. | $23.35 | 2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $22.56 | 2022 | |
| Abbott Laboratories | $18.04 | 2025 | Ultreon |
| Gilead Sciences, INC. | $12.16 | 2021 | |
| Amarin Pharma, INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.